Abstract:e14513 Background: Local recurrence of Hepatocellular Carcinoma (HCC) following potentially curative resection or ablation is an inevitable risk. T cells recognizing neoantigens are present in most cancers including HCC and offer a specific and highly immunogenic target for the personalized vaccination as an adjuvant therapy. The purpose of this study is to evaluate the safety and T cell immune response of a personalized neoantigen-based mRNA loaded dendritic cell (DC) vaccine (LK101) combined with regular ablation in patients with HCC (NCT03674073). Methods: Each patient’s fresh tumor biopsy and matched peripheral blood sample were subjected to whole-exome sequencing and RNA-sequencing. Following determination of somatic mutations and gene expression, up to 30 in silico–predicted potential neoantigens were selected with bioinformatic tool. DCs were generated from the monocytes enriched by leukapheresis, followed by transfection with neoantigen-encoding mRNA through electroporation. In total, 7 doses of LK101 were administered at 1.5×107 cells/injection intradermally with 4-dose priming weekly and 3 boosters in 4-week intervals. The primary endpoint of the clinical study was safety, and key secondary endpoints were immunogenicity, overall survival and recurrence. 24 HCC patients at HKLC stage IIa were enrolled 1:1 to ablation control arm and ablation combined with DC (LK101) arm. Results: The study was completed, patients were followed up for a median of 48.4 months and 38.8 months in vaccination arm and control arm. All of adverse events were Grade 1-2. Most frequent treatment-related adverse events are injection site reactions, inclusive of local pain (63.6%), itch (27.3%) and others (27.3%), such as redness and edema. 3 patients in ablation control arm died, whereas all vaccinated patients survived. The 1-year and 2-year recurrence rates in vaccination arm compared with control arm are 18.2%, respectively. LK101 induced neoantigen-specific T cell responses were investigated by ELISpot analysis. Overall, all patients elicited at least one measurable response. Immune responses to 60-90% of neoantigen peptides were seen post vaccination across patients. Both preexisting immune response and De Novo immune response that targeted neoantigens were observed in vaccinated patients. Moreover, both CD4 and CD8 positive effector memory T cells showed the trend of increase, and PD-1 positive T cells reduced in peripheral blood of patients after vaccination. Conclusions: Combination of LK101 with ablation therapy has a manageable safety profile, showing the evidence of immune activation and potential of prolonged survival. In combination with regular ablation, neoantigen based mRNA loaded DC vaccine is a promising immunotherapy for the treatment of HCC. Clinical trial information: NCT03674073 .

Engineering α-fetoprotein-based gene vaccines to prevent and treat hepatocellular carcinoma: review and future prospects.

Epitope-Optimized Alpha-Fetoprotein Genetic Vaccines Prevent Carcinogen-Induced Murine Autochthonous Hepatocellular Carcinoma

Immunotherapy of Hepatocellular Carcinoma with a Vaccine Based on Xenogeneic Homologous Α Fetoprotein in Mice

A First-in-human Study to Evaluate a Personalized Neoantigen-Based Mrna-Loaded Dendritic Cell Vaccine, in Combination with Ablation, in Patients with Hepatocellular Carcinoma.

Identification of α-fetoprotein-specific T cell receptors for hepatocellular carcinoma immunotherapy.

Development of A Listeria Monocytogenes-Based Vaccine Against Hepatocellular Carcinoma

Identification of novel α-fetoprotein-specific T cell receptors to redirect human T cells for hepatocellular carcinoma immunotherapy

Generation of Αgal-Enhanced Bifunctional Tumor Vaccine

Prevention of Hepatocellular Carcinoma in Mice by IL-2 and B7-1 Genes Co-Transfected Liver Cancer Cell Vaccines

Alpha fetal protein-specific hepatocellular carcinoma vaccines inhibit hepatocellular carcinoma growth in nude mice bearing human hepatocellular carcinoma

Neoantigen vaccine: An emerging immunotherapy for hepatocellular carcinoma

Autologous Tumor Vaccine for Prevention and Treatment of HCC

A Comprehensive Review on Cancer Vaccines and Vaccine Strategies in Hepatocellular Carcinoma

Engineered Cytotoxic T Lymphocytes with AFP-specific TCR Gene for Adoptive Immunotherapy in Hepatocellular Carcinoma

Personalized neoantigen vaccine combined with PD-1 blockade increases CD8(+) tissue-resident memory T-cell infiltration in preclinical hepatocellular carcinoma models

Personalized neoantigen vaccine combined with PD-1 blockade increases CD8<sup>+</sup> tissue-resident memory T-cell infiltration in preclinical hepatocellular carcinoma models

[Application of Fusion Gene Mgm-Csf/hil-2 to Specific Immunotherapy Induced by Hepatic Tumor Cell Vaccine].

Targeting Tumor‐Associated Antigens in Hepatocellular Carcinoma for Immunotherapy: Past Pitfalls and Future Strategies

Recombinant heat shock protein 70 functional peptide and alpha-fetoprotein epitope peptide vaccine elicits specific anti-tumor immunity

Autophagy enhances antitumor immune responses induced by irradiated hepatocellular carcinoma cells engineered to express hepatitis B virus X protein.

Revamping Hepatocellular Carcinoma Immunotherapy: The Advent of Microbial Neoantigen Vaccines